Tibet Aim Pharm.Inc. (002826.SZ) released its third-quarter financial report for 2025. The company's revenue for the first three quarters reached RMB 489 million, representing a year-on-year decrease of 4.65%. Net profit attributable to shareholders of the listed company surged 95.52% to RMB 81.76 million. Excluding non-recurring gains and losses, the net profit stood at RMB 39.95 million, marking a significant increase of 144.50% compared to the same period last year. Basic earnings per share were reported at RMB 0.44.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments